circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X 31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST

    31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST
  • Webcast
    X Q3 2019 Cytokinetics, Inc. Earnings Conference Call
    Oct 31, 2019 4:30 PM EDT

    Q3 2019 Cytokinetics, Inc. Earnings Conference Call
    Oct 31, 2019 4:30 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.
Toggle Summary Cytokinetics Announces Start of REDWOOD-HCM, a Phase 2 Clinical Trial of CK-3773274
Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule SOUTH SAN FRANCISCO, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that REDWOOD-HCM ( R andomized E valuation
Toggle Summary Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif. , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS).
Toggle Summary Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND
Subgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv with and without Concomitant Radicava® (edaravone) or Rilutek® (riluzole) SOUTH SAN FRANCISCO, Calif. , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new results were presented at the 30

EVENTS

There are currently no events to display.